Comment on ‘An open-label phase II study of bitopertin in adults and adolescents with erythropoietic protoporphyria or X-linked protoporphyria’

Clicks: 1
ID: 321035
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #154 of 169 articles by views in clinical and experimental dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 169 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
We read with interest the phase II BEACON study by Ross et al. on biopterin for erythropoietic protoporphyria (EPP). While the observed PPIX reductions are encouraging, several unaddressed methodological issues undermine the validity of the efficacy conclusions.
Reference Key
openalex_W7168236008 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Zhenzhen Xiao, Rui Li, Yingjian Tan
Journal clinical and experimental dermatology
Year 2026
DOI
10.1093/ced/llag299
URL
https://doi.org/10.1093/ced/llag299
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.